Medtronic plc (MDT) Earnings Call Transcripts

Medtronic plc's Latest Earnings Call - Q4 FY2026

In the fourth quarter of fiscal 2026, Medtronic plc reported revenue of $9.8 billion, reflecting a 9.9% increase year-over-year, and adjusted EPS of $1.55, exceeding expectations. For the full fiscal year, revenue reached $36.4 billion, up 8.4% reported and 5.8% organically, marking the strongest performance in a decade. Management provided guidance for fiscal 2027, projecting organic revenue growth of 6.75% to 7.25%, including a strong start in Q1 driven by an additional selling week.

Reported metrics

Guidance from management

Management expects organic revenue growth of 6.75% to 7.25% for fiscal year 2027, with a strong start anticipated in Q1 due to an additional selling week. Guidance includes a 25 basis point tailwind from the diabetes business.

What management said

I would just say, look, in Q4, we grew 6.6% despite the headwind that we had from TAVR, in particular in the U.S., as you said, Geoff. And what we've seen over the last 8 weeks is a stabilization of that business, and that's what we've modeled going forward.

Yes. And on the tariff side, I think we mentioned it in the commentary. Look, we continue to monitor the environment there, which is still a little volatile, as you mentioned. I think we continue to look at the 232 situation. On the flip side, we've incorporated sort of a status quo in tariffs. So we haven't incorporated any potential upside for reimbursements that could occur in which we have applied for. So we we t...

What analysts pressed on

Analysts expressed concerns regarding the TAVR business, particularly its recent slowdown in growth. There are worries about how this might impact overall revenue growth, especially as Medtronic navigates a competitive landscape.

Main topics on the call

• Strong Revenue Growth — Medtronic achieved $9.8 billion in revenue for Q4, up 9.9% year-over-year, with a full-year revenue of $36.4 billion, marking an 8.4% increase. CEO Geoff Martha stated, "These results represent the compounding impact of ...
• Electrophysiology (EP) Growth — Cardiac Ablation Solutions (CAS) grew 78% worldwide, with U.S. share increasing by 8 points. Martha noted, "We see significant runway for continued expansion," indicating strong future potential in this segment.
• Acquisitions and Investments — Medtronic is increasing investments in M&A, targeting higher growth segments. CFO Thierry Pieton mentioned, "We closed or announced nearly $2 billion of additional investments," indicating a strategic focus on innovation...
• Diabetes Business Spin-off — The MiniMed IPO was completed, establishing it as a stand-alone company. Management emphasized that this separation allows Medtronic to focus on faster-growing segments, with Martha stating, "Both businesses will do bett...

Read the full Medtronic plc transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 89 Medtronic plc earnings call transcripts on record, spanning January 13, 2020 to June 3, 2026. Based on this history, Medtronic plc reports quarterly. The most recent call on file is dated June 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MDT

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

89

First call

January 13, 2020

Most recent

June 3, 2026

Reporting cadence

quarterly